Is PARD setting up for solid gains again?

Poniard Pharmaceuticals, Inc. (PARD)

From marketwatch news dated Jan/01/2010, "We expect to submit efficacy and safety data from the Phase 3 SPEAR trial for potential presentation at the American Society of Clinical Oncology 2010 Annual Meeting in June."

From news dated May/10/2010 "Poniard plans to release Phase III data from a lung-cancer clinical trial for its chemotherapy agent picoplatin on June 5 at the annual meeting of the American Society of Clinical Oncology" link

Current PPS: 1.3
O/S - 47m
Link to google finance
Link to company website

>> Subscribe to our posts.
Check March performance.

*Please do your own research before buying any stocks listed on this blog. We cannot guarantee the accuracy of our findings related to any stock.